HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

House Subcommittee Hearing Explores Alleged Gaps In Cosmetic Safety

This article was originally published in The Rose Sheet

Executive Summary

Legislative proposals that would require cosmetics companies to report adverse events to FDA and register their manufacturing facilities were the focus of discussion among panelists testifying on Capitol Hill May 14 on a draft version of the Food and Drug Administration Globalization Act of 2008

You may also be interested in...



2018 In Review: US Midterm Mania Stifles Cosmetics Regulatory Reform Momentum

Despite repeated stakeholder assertions of being “closer than ever” to modernizing cosmetics regulations, the 115th Congress ended with reform legislation stranded in committee. The Personal Care Products says midterm elections diverted lawmakers’ attention from unresolved issues, likely including possible preemption terms to put a lid on growing state and local requirements.

What Does FDA Deem A "Serious Adverse Event"? Matrixx Learns The Hard Way

A narrower interpretation of "serious adverse event" - compared with FDA's definition - is costing Matrixx Initiatives at least $10 million dollars with the recall of its intranasal Zicam products - assuming FDA cannot be convinced to reverse its position

What Does FDA Deem A "Serious Adverse Event"? Matrixx Learns The Hard Way

A narrower interpretation of "serious adverse event" - compared with FDA's definition - is costing Matrixx Initiatives at least $10 million dollars with the recall of its intranasal Zicam products - assuming FDA cannot be convinced to reverse its position

Related Content

UsernamePublicRestriction

Register

RS015436

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel